UK markets open in 5 hours 44 minutes

Almirall, S.A. (0O9B.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
9.44+0.12 (+1.34%)
At close: 03:53PM BST
Full screen
Previous close9.31
Bid9.23 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Avg. volume42,812
Market cap2.149B
Beta (5Y monthly)0.40
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.18 (2.03%)
Ex-dividend date12 May 2023
1y target estN/A

    Almirall's Ebglyss poised for EU approval, challenging Sanofi and Regeneron’s Dupixent

    Almirall, the Spanish pharmaceutical company, is on the brink of securing European Union (EU) approval for its IL-13 inhibitor lebrikizumab, marketed as Ebglyss, for atopic dermatitis treatment. The European Medicines Agency's (EMA) human medicines committee has recommended the drug's approval, setting up a challenge to the market-leading Dupixent, produced by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN).